{"created":"2023-05-18T10:10:59.785550+00:00","id":2685,"links":{},"metadata":{"_buckets":{"deposit":"180c0843-39b8-42c0-a423-9eda9330fafe"},"_deposit":{"created_by":5,"id":"2685","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"2685"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00002685","sets":["205:206:210"]},"author_link":["12914","12915","12916","12917","12918","12919","12920"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"37","bibliographicPageStart":"27","bibliographicVolumeNumber":"32","bibliographic_titles":[{"bibliographic_title":"山梨医科学雑誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Yamanashi medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ohta, Masato","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Satoh, Kaneo","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukasawa, Isao","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hosokawa, Kazuya","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oonishi, Tomoko","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakagomi, Junko","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ozaki, Yukio\\r","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"Introduction: Cilostazol inhibits phosphodiesterase, with resultant increase in intracellular cyclic AMP, leading to platelet inhibition, particularly in the presence of prostaglandin E1 (PGE1). This study aimed to establish a cilostazol monitoring assay, using whole blood samples.\\r Methods: Platelet aggregation in the presence or absence of indicated concentrations of PGE1 were assessed using VerifyNowR, MultiplateR and Total Thrombus-formation Analysis System (T-TASR).\\r Results: In the presence of added PGE1, cilostazol inhibited in vitro platelet aggregation of VerifyNow, with the aspirin test by 19% and the IIb/IIIa test by 44%, respectively. After a single oral uptake of cilostazol in healthy volunteers, cilostazol decreased platelet aggregation, with the IIb/IIIa test by 46% and with the P2Y12 test by 24%, respectively. Multiplate or T-TAS failed to detect cilostazol effi cacy both in vitro and ex vivo. VerifyNow IIb/IIIa tests were used to monitor cilostazol effi cacy on cerebral infarction patients. Compared with pre-therapy blood samples, those after cilostazol uptake showed signifi cant inhibition of platelet aggregation in the presence of 3 nM (37%) and 10 nM PGE1 (69%).\\r Conclusion: The IIb/IIIa tests of VerifyNow in the presence of 10 nM PGE1 is the most suitable tool for monitoring assessing cilostazol.","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00002678","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨大学医学会","subitem_publisher_language":"ja"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA11839837","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1348-5091","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"YMJ32-1-027to037.pdf","filesize":[{"value":"743.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"YMJ32-1-027to037.pdf","objectType":"fulltext","url":"https://yamanashi.repo.nii.ac.jp/record/2685/files/YMJ32-1-027to037.pdf"},"version_id":"680cea3a-b467-4ec5-bd14-27c217db2951"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"cilostazol","subitem_subject_language":"en"},{"subitem_subject":"whole blood platelet function test","subitem_subject_language":"en"},{"subitem_subject":"prostaglandin E1","subitem_subject_language":"en"},{"subitem_subject":"anti-platelet therapy\\r ","subitem_subject_language":"en"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"5","path":["210"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2017-07-11"},"publish_date":"2017-07-11","publish_status":"0","recid":"2685","relation_version_is_last":true,"title":["<Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests"],"weko_creator_id":"5","weko_shared_id":-1},"updated":"2023-10-11T07:18:08.857195+00:00"}